Professor Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, presents extensive olpasiran data from the Phase 2 OCEAN(a)-DOSE trial in patients with elevated Lp(a), including effects on apoB-associated oxidised phospholipids, and discusses progress with the ongoing Phase 3 OCEAN(a)-OUTCOMES and OCEAN(a)-PreEvent trials.
Please login or create a FREE account to view this content
Educational Partners of the 2nd Closed Scientific Expert Meeting of the Editorial Board
Principal partners:
Guest partners:
